Pacific Capital Partners Ltd Cuts Holdings in Danaher Corporation $DHR

Key Points

• Pacific Capital Partners Ltd has reduced its stake in Danaher Corporation by 42.9%, selling 15,000 shares and retaining 20,000 shares, marking Danaher as 9th in its portfolio.
• Danaher reported a quarterly EPS of $1.80, exceeding expectations, with a revenue of $5.94 billion, up 3.4% year-over-year.
• A quarterly dividend of $0.32 per share has been declared, with an annualized yield of 0.7%, to be paid on October 31st.

Pacific Capital Partners Ltd lowered its position in Danaher Corporation (NYSE:DHR - Free Report) by 42.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,000 shares of the conglomerate's stock after selling 15,000 shares during the quarter. Danaher makes up approximately 3.7% of Pacific Capital Partners Ltd's portfolio, making the stock its 9th biggest position. Pacific Capital Partners Ltd's holdings in Danaher were worth $3,951,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. MGO One Seven LLC boosted its stake in shares of Danaher by 485.7% during the first quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate's stock valued at $5,145,000 after purchasing an additional 20,813 shares during the period. UniSuper Management Pty Ltd raised its holdings in Danaher by 1.6% in the first quarter. UniSuper Management Pty Ltd now owns 170,505 shares of the conglomerate's stock worth $34,954,000 after purchasing an additional 2,667 shares in the last quarter. Asahi Life Asset Management CO. LTD. bought a new position in Danaher in the first quarter worth $539,000. Horizon Financial Services LLC raised its holdings in Danaher by 20,400.0% in the first quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate's stock worth $1,681,000 after purchasing an additional 8,160 shares in the last quarter. Finally, Blue Whale Capital LLP raised its holdings in Danaher by 5.0% in the first quarter. Blue Whale Capital LLP now owns 346,246 shares of the conglomerate's stock worth $70,980,000 after purchasing an additional 16,500 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Wall Street Zen upgraded Danaher from a "hold" rating to a "buy" rating in a report on Friday, June 27th. Guggenheim restated a "buy" rating and set a $250.00 price target on shares of Danaher in a report on Wednesday, July 23rd. Wells Fargo & Company reduced their price target on Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a report on Wednesday, July 23rd. Royal Bank Of Canada set a $241.00 price target on Danaher in a report on Tuesday, September 2nd. Finally, Evercore ISI reduced their price target on Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Seventeen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $246.35.

Danaher Stock Performance

NYSE DHR traded up $1.89 during trading hours on Tuesday, hitting $190.43. The company's stock had a trading volume of 4,817,643 shares, compared to its average volume of 3,203,970. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $279.90. The company's 50 day simple moving average is $200.77 and its two-hundred day simple moving average is $198.59. The company has a market cap of $136.36 billion, a P/E ratio of 40.52, a price-to-earnings-growth ratio of 2.63 and a beta of 0.75. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. The business had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The business's quarterly revenue was up 3.4% compared to the same quarter last year. During the same period in the previous year, the company posted $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, sell-side analysts expect that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be issued a $0.32 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.7%. Danaher's payout ratio is currently 27.23%.

Insider Buying and Selling

In other news, Director Teri List sold 2,778 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director directly owned 20,751 shares of the company's stock, valued at $4,379,706.06. This represents a 11.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 11.20% of the company's stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.